These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 21968130)

  • 1. Reduction of alloantibodies via proteasome inhibition in cardiac transplantation.
    Patel J; Everly M; Chang D; Kittleson M; Reed E; Kobashigawa J
    J Heart Lung Transplant; 2011 Dec; 30(12):1320-6. PubMed ID: 21968130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lung transplantation across donor-specific anti-human leukocyte antigen antibodies: utility of bortezomib therapy in early graft dysfunction.
    Stuckey LJ; Kamoun M; Chan KM
    Ann Pharmacother; 2012 Jan; 46(1):e2. PubMed ID: 22202499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abrogation of anti-HLA antibodies via proteasome inhibition.
    Trivedi HL; Terasaki PI; Feroz A; Everly MJ; Vanikar AV; Shankar V; Trivedi VB; Kaneku H; Idica AK; Modi PR; Khemchandani SI; Dave SD
    Transplantation; 2009 May; 87(10):1555-61. PubMed ID: 19461494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HLA desensitization with bortezomib in a highly sensitized pediatric patient.
    May LJ; Yeh J; Maeda K; Tyan DB; Chen S; Kaufman BD; Bernstein D; Rosenthal DN; Hollander SA
    Pediatr Transplant; 2014 Dec; 18(8):E280-2. PubMed ID: 25174602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of children undergoing cardiac transplantation with high Panel Reactive Antibodies.
    Asante-Korang A; Jacobs JP; Ringewald J; Carapellucci J; Rosenberg K; McKenna D; McCormack J; Wilmot I; Gjeldum A; Lopez-Cepero M; Sleasman J
    Cardiol Young; 2011 Dec; 21 Suppl 2():124-32. PubMed ID: 22152539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of bortezomib on donor specific antibody reduction in patients with antibody mediated rejection.
    Hardinger KL; Murillo D
    Clin Transpl; 2011; ():401-8. PubMed ID: 22755438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteasome inhibition by bortezomib: effect on HLA-antibody levels and specificity in sensitized patients awaiting renal allograft transplantation.
    Guthoff M; Schmid-Horch B; Weisel KC; Häring HU; Königsrainer A; Heyne N
    Transpl Immunol; 2012 Jun; 26(4):171-5. PubMed ID: 22326708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Late antibody-mediated rejection after heart transplantation following the development of de novo donor-specific human leukocyte antigen antibody.
    Hodges AM; Lyster H; McDermott A; Rice AJ; Smith JD; Rose ML; Banner NR
    Transplantation; 2012 Mar; 93(6):650-6. PubMed ID: 22245878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Desensitization protocol using bortezomib for highly sensitized patients awaiting heart or lung transplants.
    Weston M; Rolfe M; Haddad T; Lopez-Cepero M
    Clin Transpl; 2009; ():393-9. PubMed ID: 20524304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful kidney transplantation after desensitization using plasmapheresis, low-dose intravenous immunoglobulin, and rituximab in highly sensitized patients: a single-center experience.
    Jin MK; Cho JH; Kwon O; Hong KD; Choi JY; Yoon SH; Park SH; Kim YL; Kim CD
    Transplant Proc; 2012 Jan; 44(1):200-3. PubMed ID: 22310614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection.
    Waiser J; Budde K; Schütz M; Liefeldt L; Rudolph B; Schönemann C; Neumayer HH; Lachmann N
    Nephrol Dial Transplant; 2012 Mar; 27(3):1246-51. PubMed ID: 21852274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteasome inhibitor treatment of antibody-mediated allograft rejection.
    Woodle ES; Alloway RR; Girnita A
    Curr Opin Organ Transplant; 2011 Aug; 16(4):434-8. PubMed ID: 21753709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Four-year allograft survival in a highly sensitized combined liver-kidney transplant patient despite unsuccessful anti-HLA antibody reduction with rituximab, splenectomy, and bortezomib.
    Koch M; Gräser C; Lehnhardt A; Pollok JM; Kröger N; Verboom M; Thaiss F; Eiermann T; Nashan B
    Transpl Int; 2013 Aug; 26(8):e64-8. PubMed ID: 23672514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteasome inhibitor therapy for antibody-mediated rejection.
    Woodle ES; Walsh RC; Alloway RR; Girnita A; Brailey P
    Pediatr Transplant; 2011 Sep; 15(6):548-56. PubMed ID: 21884344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High immunologic risk living donor kidney transplant using bortezomib in a novel induction regimen without acute antibody mediated rejection.
    Dunn TB; Borja-Cacho D; Chinnakotla S; Finger E; Tamayo G; Verghese P; Kim Y; Manivel C; Kandaswamy R; Matas A; Pruett T; Noreen H; Krefting P; Maurer D
    Clin Transpl; 2011; ():381-7. PubMed ID: 22755435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of anti-HLA antibodies in sensitized kidney transplant candidates subjected to desensitization with intravenous immunoglobulin and rituximab.
    Lobashevsky AL; Higgins NG; Rosner KM; Mujtaba MA; Goggins WC; Taber TE
    Transplantation; 2013 Jul; 96(2):182-90. PubMed ID: 23778648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients.
    Morrow WR; Frazier EA; Mahle WT; Harville TO; Pye SE; Knecht KR; Howard EL; Smith RN; Saylors RL; Garcia X; Jaquiss RD; Woodle ES
    Transplantation; 2012 Feb; 93(3):319-24. PubMed ID: 22179403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Highly Sensitized Patients: Miami Transplant Institute Experience.
    Mattiazzi AD; Centeno A; Amador A; Fernandez-Bango C; Scowby CD; O'Rourke M; Hill-Matthie T; Patel R; Barrios F; Ruiz P; Chen L; Saghesima J; Ciancio G; Burke GW; Goldstein M; Chandar J; Contreras G; Roth D; Kupin W; Guerra G; Vianna R
    Clin Transpl; 2014; ():171-8. PubMed ID: 26281142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kidney transplant in highly sensitized patients after desensitization with plasmapheresis and low-dose intravenous immunoglobulin.
    Yuan XP; Wang CX; Gao W; Fu Q; He XS
    Exp Clin Transplant; 2010 Jun; 8(2):130-5. PubMed ID: 20565369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Late antibody-mediated rejection in renal allografts: outcome after conventional and novel therapies.
    Gupta G; Abu Jawdeh BG; Racusen LC; Bhasin B; Arend LJ; Trollinger B; Kraus E; Rabb H; Zachary AA; Montgomery RA; Alachkar N
    Transplantation; 2014 Jun; 97(12):1240-6. PubMed ID: 24937198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.